TEV-50717 for Cerebral Palsy

"There are currently 5 ongoing clinical trials for TEV-50717 in 21 cities and 11 countries. The earliest study was completed in 2020 and involved 45 patients. It successfully completed Phase 3 drug approval. In the two years since, 9 more trials have been initiated."

"This specific trial has completed recruitment, with the last update on November 9th, 2020. However, there are presently 174 other studies related to cerebral palsy and 5 trials for TEV-50717 that are actively enrolling participants."

"This trial is looking for 45 young patients, aged 6 to 18, that have been diagnosed with cerebral palsy. Most importantly, potential participants must meet the following conditions: The patient must be able to swallow TEV-50717 whole, additional criteria apply (please contact the study's lead investigator for more information), the patient completed parent Study TV50717-CNS-30080, and finally the patient must weigh a minimum of 12 kg (26 lb) on day 1 of this study."

"In order to qualify for this clinical trial, applicants must be between 6 and 18 years old. Out of the 163 total clinical trials involving patients under the age of 18, this is one of 32 that also includes patients over the age of 65."

"Presently, 5 different clinical trials are underway that focus on TEV-50717. Of these active studies, 2 have reached Phase 3. Most of the research locations for this potential treatment are situated in Philadelphia; however, there are a total of 70 sites running trials across the United States of America."

"This study's primary goal is to monitor the number of participants with adverse events over a 54-week period. Secondary outcomes include the Unified Huntington's disease Rating Scale-Total Maximal Chorea (centrally read) and the Movement Disorder - Childhood Rating Scale Part II (centrally read). The former assesses the severity of the movement disorder, while the latter provides a general assessment of motor function."

"20 enrolment centres for this trial exist, some of which are Teva Investigational Site 14227 in Loma Linda, Teva Investigational Site 14228 in Houston, and Teva Investigational Site 14295 in San Diego."

"There is some efficacy data from Phase 3 trials to support the safety of TEV-50717, which our team has rated a 3."

"This medical trial is not currently looking for participants, as reflected on clinicaltrials.gov. The listing was originally posted on February 4th 2020 and last updated on November 9th 2022. There are, however, 179 other trials actively recruiting patients at this time."